From Wikipedia, the free encyclopedia - View original article
|This article needs additional citations for verification. (January 2012)|
Somnoplasty (composed of the Latin root somnus meaning sleep, and the Greek word plastia meaning molding or formation) is a medical treatment approved by the Food and Drug Administration (FDA) to treat three conditions: habitual snoring, chronic nasal obstruction, and obstructive sleep apnea (OSA) using radiofrequency ablation to shrink the tissues that are causing the problem.
The patient is given a local anesthetic and a special needle-like electrode with an insulating sleeve covering all but the tip, that delivers RF energy under the surface of the tissue is used. The electrode is used to administer controlled, low-power RF energy to create coagulative (clotting) lesions, where tissue is denatured, beneath the mucosa (lining) of the targeted areas:
Note: the actual areas targeted depends on each individual's specific anatomy, so the above are just general associations.
After 6-8 weeks the lesions are naturally resorbed as the necrotic tissue is swept away and the surface sinks to fill the void, which reduces the volume of the tissue while stiffening what remains. When this occurs the airway is enlarged, allowing a less-restricted flow of air. In addition, the scar tissue at the margins of the lesion is relatively firm, and less inclined to contribute to snoring. Several follow-up treatments are usually required to obtain the desired results. Most insurance companies do not cover somnoplasty since it is not a widely accepted treatment for sleep apnea.
Somnoplasty was invented by Stuart D. Edwards, and Ingemar Henry Lundquist of Menlo Park, California. The original patent assignee was Vidamed, Inc. It is currently marketed by Somnus Medical Technologies, Inc. of Sunnyvale, California.
|This medical treatment–related article is a stub. You can help Wikipedia by expanding it.|